Embedding environmental sustainability into pharma’s DNA

Embedding environmental sustainability into pharma’s DNA

As the climate crisis escalates, so too does scrutiny of how companies are addressing the problems.

The pharmaceutical (pharma) industry’s involvement in environmental issues is multifaceted, with implications for the entire product value chain. From research and development (R&D) and supply chain (procurement, manufacturing, transportation, logistics and other services), to patient engagement, modes of delivery and the disposal of products, all aspects of the process are affected.

Although there are complex challenges to overcome, there are also many opportunities to accelerate the pace of change and unlock new business prospects. To achieve their sustainability ambitions, pharma companies need to undergo a fundamental transformation spearheaded by strong leadership, enhanced collaboration and a willingness to innovate with evidence-based improvement initiatives embedded across the industry.

Download our report

Download

Contacts

Karen Taylor

UK Centre for Health Solutions

Emily May

Life Sciences Insight Lead

James Gregson

UK Life Sciences & Healthcare industry leader

David Rakowski

Product Decarbonisation Lead, Health and Life Sciences